INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

4,771 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

An expert overview of the literature, useful as background reading.

325 studies · page 1 of 14

2024 / Narrative review

Gut hormones regulate appetite and weight, while drugs targeting their receptors and environmental factors influence these pathways.

This review summarizes recent research on how gut hormones interact with the brain to influence appetite and body weight. Ghrelin acts as an orexigenic hormone, while GLP-1, GIP, CCK, PYY, and OXM act as anorexigenic hormones, with actions extending into systems such as adipose tissue and high-order thinking. Environmental factors, including meal schedule, food contents and quality, exercise type, and sleep deprivation, influence these gut hormone pathways. Additionally, studies show that retatrutide (a triple-agonist of GLP-1, GIP, and glucagon receptor) and orforglipron (a GLP-1 receptor partial agonist) promote weight loss and improve metabolic parameters associated with obesity.

Hong SH, Choi KM Curr Opin Endocrinol Diabetes Obes, 2024. PMID 38511400

2024 / Narrative review

Gut microbiota and its metabolites interact with incretin hormones to influence host satiety, food intake, and metabolic regulation in obesity.

This review examines the relationships between incretin hormones, gut microbiota, and obesity. Gastrointestinal incretins such as GIP and GLP-1 are secreted following nutrient intake and impact lipid metabolism, gastric emptying, appetite, and body weight. The gut microbiota influences host metabolism by modulating incretin secretion via enteroendocrine cells, with microbial metabolites like short-chain fatty acids and indole directly stimulating incretin release. Additionally, incretin-based therapies and bariatric surgery are associated with increases in gut bacterial richness and diversity.

Angelini G, Russo S, Mingrone G Peptides, 2024. PMID 38636809

2023 / Narrative review

A review outlines the benefits and uncertainties of new weight loss drugs, noting profound caloric reductions may warrant nutritional deficiency testing.

This review evaluates the pros and cons of newer weight loss medications like semaglutide and tirzepatide, noting short-term weight losses of -15% to -20% from baseline. The authors note that profound caloric reductions from these medications should prompt baseline or ongoing nutritional deficiency testing and dietary recommendations. However, long-term adherence, cost, access, supply chain issues, and long-term impacts on mental and physical health remain unknown.

Moyad MA Curr Urol Rep, 2023. PMID 37659049

2023 / Narrative review

A review outlines therapeutic milestones in obesity management, including leptin, melanocortin agonists, incretins, and metabolic surgery.

This review summarizes scientific milestones and therapies developed to address obesity and its cardiometabolic comorbidities. It highlights key developments starting from the discovery of leptin, melanocortin receptor agonists for syndromic obesity, incretin therapies including GLP-1 analogs and unimolecular combinations, and metabolic and bariatric surgery. The authors emphasize that this expanding therapeutic armamentarium warrants a coordinated multidisciplinary approach, such as cardiometabolic expertise centers, to address obesity and its complications.

Kokkorakis M, Katsarou A, Katsiki N, et al. Metabolism, 2023. PMID 37689110

2023 / Review

A review discusses current and emerging anti-obesity medications, including lipase inhibitors, GLP-1 agonists, leptin analogs, and MC4R agonists.

Obesity is a major public health concern associated with conditions like hypertension, type 2 diabetes, stroke, and cancer, affecting over a third of adults in the United States. While standard pharmacological agents such as lipase inhibitors and GLP-1 receptor agonists reduce weight gain by inhibiting fat absorption or stimulating satiety hormones, they are not effective for genetic disorders like Bardet-Biedl syndrome or POMC deficiency. Emerging therapies, including leptin analogs and MC4R agonists, target these genetic or hormonal causes to help regulate energy balance and appetite. The review discusses clinical trials, efficacy, FDA-approved indications, contraindications, and serious side effects of these medication classes.

Brandfon S, Eylon A, Khanna D, et al. Cureus, 2023. PMID 37937009

2023 / Editorial

Obesity and weight loss involve complex interactions between metabolism, the microbiome, social factors, physical comorbidities, and mental health.

This editorial discusses the multifaceted challenges surrounding weight loss and obesity in science and public health. It highlights that both biological aspects (such as metabolism and the microbiome) and social factors (like poverty and inadequate healthcare) contribute to obesity. While excess weight carries comorbidities that reduce life expectancy, evidence indicates individuals can be overweight and healthy, though obesity remains linked to poor mental health influenced by societal stigma.

Thorp HH Science, 2023. PMID 38096295

2022 / Narrative review

GLP-1 receptor agonists are effective for obesity and T2DM, but their therapeutic effects are not fully congruent with endogenous GLP-1 actions.

This review examines the physiological functions of GLP-1 and its development into pharmaceuticals for obesity and type 2 diabetes (T2DM). GLP-1 receptor agonists are highlighted as effective anti-obesity agents and recommended second-line therapies for T2DM, particularly for patients with increased cardiovascular risk. The author discusses proglucagon processing across tissues and notes that the relationship between endogenous GLP-1 actions and the clinical effects of agonists is far from congruent and generally poorly understood.

Holst JJ J Intern Med, 2022. PMID 34982496

2020 / Narrative review

Features of processed foods are linked to western diseases and may negatively affect the gut microbiota.

This review examines literature regarding the relationship between features of processed foods and the etiology of obesity and non-communicable diseases. The reviewed features include micronutrient and energy density, food additives, and the generation of advanced glycation end products from thermal processing. Overall, literature indicates these factors can be linked to western ailments and can have a potential negative impact on human microbiota. The authors propose that empirical evidence is growing for distressed gut microbiota as a mechanism explaining how food processing features could harm human health.

Shows an association, not proof of cause and effect.

Miclotte L, Van de Wiele T Crit Rev Food Sci Nutr, 2020. PMID 30945554

2020 / Narrative review

A review notes that fenugreek extract and its bioactive compounds exhibit antidiabetic and anti-obesity activities in animal and human studies.

This review explores the bioactivity, clinical application, phytochemicals, products, markets, and patents related to fenugreek. More than 100 phytochemicals have been isolated from fenugreek seeds, mainly comprising polysaccharides, saponins, alkaloids, phenolic acids, and flavonoids. Fenugreek extract and its bioactive compounds showed antidiabetic and anti-obesity activity in both animal and human studies. The authors note that China currently lacks research on fenugreek in both depth and width.

Yao D, Zhang B, Zhu J, et al. Crit Rev Food Sci Nutr, 2020. PMID 31286789

2020 / Narrative review

A narrative review suggests ultra-processed Western diet components may influence metabolic and neurobiological pathways relevant to eating disorders.

This narrative review examined the implications of changing dietary patterns, specifically the rise of ultra-processed (NOVA-4) foods, on metabolic and neurobiological pathways related to eating disorders. The increased intake of sugars and food additives has metabolic consequences, including triggering insulin and glucose responses, stimulating appetite, and affecting endocrine pathways, neurobiology, and the microbiome. The authors propose integrating metabolic responses to modern highly processed foods into existing psychological models to improve eating disorder research and treatment outcomes.

Ayton A, Ibrahim A Nutr Rev, 2020. PMID 31846028

2020 / Narrative review

A whole food plant-based diet may offer benefits that slow chronic kidney disease progression and delay kidney failure.

This review examines the potential of a whole food plant-based (WFPB) diet to ameliorate chronic kidney disease (CKD). Evidence suggests a WFPB diet may slow CKD progression, decrease cardiovascular disease incidence, lower rates of diabetes and obesity, and reduce inflammation and cholesterol, thereby delaying kidney failure and dialysis initiation. Plant-based protein is reported to be alkaline-producing, anti-inflammatory, and renoprotective, contrasting with animal protein which promotes acidity, inflammation, and hyperfiltration. The authors note that macronutrient and micronutrient content must be carefully adjusted to prevent malnutrition, and further research is required to confirm biological plausibility and feasibility in CKD patients.

Adair KE, Bowden RG Nutrients, 2020. PMID 32268544

2020 / Narrative review

A review notes lifestyle modifications like low sodium diet and weight loss can help control hypertension in African Americans.

This review examined literature from PubMed, guideline reports, and newer publications regarding hypertension and COVID-19 in African Americans. It highlights that the increased prevalence and risks of hypertension are primarily due to environmental and lifestyle factors, such as poor diet and adverse social determinants. Blood pressure control can be supported through lifestyle changes, including a low-sodium diet, weight loss, and physical activity, alongside pharmacological or novel treatments when needed. Additionally, existing comorbidities like hypertension and obesity contribute to worse COVID-19 outcomes in this population.

Ferdinand K, Batieste T, Fleurestil M J Natl Med Assoc, 2020. PMID 32563685

2020 / Narrative review with systematic search

A review of 43 studies found ultra-processed food consumption was linked to at least one adverse health outcome in 37 studies, with no beneficial outcomes found.

This narrative review systematically searched and appraised studies examining associations between ultra-processed food (UPF) intake and health outcomes in healthy participants. Out of 43 reviewed studies, 37 found UPF exposure was associated with at least one adverse health outcome. In adults, reported associations included overweight, obesity, cardio-metabolic risks, cancer, type-2 diabetes, cardiovascular diseases, irritable bowel syndrome, depression, frailty conditions, and all-cause mortality; in children and adolescents, outcomes included cardio-metabolic risks and asthma. No study reported an association between UPF and beneficial health outcomes, and the authors note that most findings were derived from observational studies.

Shows an association, not proof of cause and effect.

Elizabeth L, Machado P, Zinöcker M, et al. Nutrients, 2020. PMID 32630022

2019 / Narrative review

A review outlines weight loss-induced remission of type 2 diabetes and notes stable beta-cell function if weight regain is prevented.

Following a James Lind Alliance survey identifying diabetes reversal as the top research priority among people with type 2 diabetes, this review summarizes current evidence on weight loss-induced remission. Current data indicate long-term stable β-cell function occurs if weight regain is prevented, whereas returning to previous weight leads to recurrence. The review also notes that the chance of achieving reversal steadily diminishes with increasing duration of type 2 diabetes.

Taylor R, Barnes AC Diabet Med, 2019. PMID 30378706

2019 / Narrative review

Modifying diet and lifestyle through weight maintenance, balanced energy intake, and exercise is key to preventing and managing NAFLD.

This review summarizes existing literature on therapeutic strategies for the prevention and management of non-alcoholic fatty liver disease (NAFLD), emphasizing nutritional status and its clinical impact. It notes that nutritional status and food compounds influence NAFLD development and progression. The authors state that the best strategy to prevent and treat NAFLD involves dietary and lifestyle modifications, including maintaining a healthy weight, consuming a well-balanced diet with appropriate energy intake, and increasing physical activity or strength training.

Mansour A, Hekmatdoost A, Mirmiran P J Dig Dis, 2019. PMID 30968561

2019 / Narrative review

Substantial weight loss can reverse type 2 diabetes by removing excess fat from the liver and pancreas.

This review discusses clinical and pathophysiological studies showing that type 2 diabetes is largely driven by reversible fat accumulation in the liver and pancreas. Removal of this excess fat through substantial weight loss can normalize hepatic insulin responsiveness and allow recovery of acute insulin secretion by beta cells, normalizing blood glucose. In the primary care-based DiRECT trial, weight loss mediated type 2 diabetes remission in 46% of individuals at 12 months and 36% at 24 months.

Taylor R, Al-Mrabeh A, Sattar N Lancet Diabetes Endocrinol, 2019. PMID 31097391

2019 / Case report and literature review

A whole food plant-based diet alongside medical therapy was followed by weight loss and normalized heart function in a patient with heart failure.

A 54-year-old female presenting with grade 3 obesity (BMI 45.2 kg/m2), type II diabetes (A1c 8.1%), and heart failure with depressed left ventricular systolic function transitioned to a whole food plant-based diet alongside guideline-directed medical therapy. Over five and a half months, she lost 22.7 kg, reversed her diabetes without diabetes medications, and normalized her left ventricular systolic function. The authors noted that causality cannot be determined from this case report.

Allen KE, Gumber D, Ostfeld RJ Front Nutr, 2019. PMID 31245377

2019 / Narrative review

Ultra-processed food consumption is associated with weight gain and may contribute to metabolic syndrome and chronic disease.

This review describes US dietary trends, food quality, and the potential role of ultra-processed foods in obesity, chronic diseases, and all-cause mortality. Human trials have identified ultra-processed foods as contributing to decreased satiety, increased eating rates, worsening biochemical markers, and greater weight gain. In contrast, populations consuming minimally processed, high-fiber diets with low meat intake have lower chronic disease and obesity rates and live longer disease-free.

Shows an association, not proof of cause and effect.

Laster J, Frame LA Curr Treat Options Gastroenterol, 2019. PMID 31786723

2019 / Narrative review

A review suggests plant-based diets may reduce the risk of heart disease and possibly cancer among Black individuals in the United States.

This review evaluated the evidence on plant-based diets and health outcomes, examining how these benefits translate to Black individuals in the United States. Although substantial evidence supports plant-based diets in the general population, little research has focused specifically on Black populations. Available data suggest that plant-based diets may reduce the risk of heart disease and possibly cancer in this group. The authors note that more research is needed on cardiovascular risk factors, cancer subtypes, and other chronic diseases, emphasizing the need for culturally appropriate interventions.

Shows an association, not proof of cause and effect.

Sterling SR, Bowen SA Nutrients, 2019. PMID 31810250

2019 / Updated systematic review of meta-analyses

Nut consumption was linked to lower CVD, CHD, and stroke mortality/incidence, and reduced fasting glucose, total cholesterol, and LDL-C in meta-analyses.

An updated electronic search of PubMed/MEDLINE, CINAHL, and Cochrane Library identified seven new meta-analyses examining nut consumption and cardiometabolic diseases. Comparing high with low consumption categories, nut intake significantly decreased CVD mortality (-19% to -25%; n = 4), CHD mortality (-24% to -30%; n = 3), stroke mortality (-17% to -18%; n = 3), CVD incidence (-15% to -19%; n = 4), CHD/CAD incidence (-17% to -34%; n = 8), and stroke incidence (-10% to -11%; n = 6). Compared with control diets, nut consumption significantly reduced fasting glucose (0.08 to 0.15 mmol/L; n = 6), total cholesterol (0.021 to 0.30 mmol/L; n = 10), and LDL-C (0.017 to 0.26 mmol/L; n = 10). Body weight and blood pressure were not significantly affected.

Shows an association, not proof of cause and effect.

Kim Y, Keogh JB, Clifton PM Int J Environ Res Public Health, 2019. PMID 31817639

2019 / Narrative review

A review suggests that a plant-based diet may serve as a valuable tool for managing atrial fibrillation risk factors.

Atrial fibrillation affects an estimated 34 million individuals globally and carries a significant burden of morbidity and mortality. This review examines evidence regarding the use of a whole-food plant-based diet—emphasizing grains, legumes, vegetables, fruits, and nuts while excluding most or all animal products—for managing atrial fibrillation risk factors. It highlights effects on cardiovascular and metabolic factors including hypertension, coronary artery disease, diabetes, obesity, inflammation, and subclinical atherosclerosis.

Storz MA, Helle P J Arrhythm, 2019. PMID 31844466

2018 / Case-based review

A case-based review discusses non-surgical multidisciplinary metabolic rehabilitation and surgical options for obese adults with type 2 diabetes.

This article discusses two clinical cases and reviews practical approaches to managing obesity and type 2 diabetes, focusing on non-surgical metabolic rehabilitation. The authors note that referral to a multidisciplinary outpatient program may be necessary for more complicated patients, and it is not uncommon for patients to lose between 10-20% of their initial weight. Despite this, metabolic surgery may be required for further weight loss and long-term maintenance. Based on clinical experience, the authors suggest intensive, multidisciplinary rehabilitation with supervised exercise as the gold standard of care.

Bishay RH, Kormas N Curr Diabetes Rev, 2018. PMID 28359235

2018 / Narrative review of observational studies and RCTs

Diets such as the Mediterranean diet and low-calorie weight loss diets are linked to improvements in men's sexual health parameters.

Researchers reviewed literature from 1977 through 2017 examining the relationship between diet or dietary patterns and male sexual health. They evaluated 13 studies on erectile dysfunction, 15 on testosterone levels (consisting of observational studies and randomized controlled trials), and 13 on semen analysis parameters (consisting only of cross-sectional and case-control studies). Erectile dysfunction appeared to lessen with adherence to the Mediterranean diet, while overweight or obese men losing weight on low-fat, low-calorie diets showed improvements in erectile function and testosterone. A Western diet was associated with lower semen quality.

Shows an association, not proof of cause and effect.

NANO counterpoint →

La J, Roberts NH, Yafi FA Sex Med Rev, 2018. PMID 28778698

2018 / Narrative review

A low-energy diet induces negative energy balance that can normalize liver and pancreas fat and reverse early type 2 diabetes.

This review details research using a low-energy diet to elucidate and reverse pathophysiological changes in type 2 diabetes. Negative energy balance triggers a profound fall in liver fat content, normalizing hepatic insulin sensitivity within 7 days. Continued negative energy balance lowers liver triacylglycerol export and raised pancreas fat content, re-establishing normal first-phase insulin secretion and plasma glucose control in early type 2 diabetes. A structured 'One, Two' approach of weight loss followed by weight maintenance has enabled motivated individuals to reverse type 2 diabetes and remain normoglycaemic over years.

Taylor R, Barnes AC Diabetologia, 2018. PMID 29143063